These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 26184711)

  • 41. [Chickenpox and shingles: one virus, two diseases and current vaccination recommendations in Switzerland].
    Eckert N; Masserey Spicher V
    Ther Umsch; 2016; 73(5):247-52. PubMed ID: 27268447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Active immunoprophylaxis to reduce clinical impact of Herpes Zoster and its complications].
    Marino MG; Bagnato B; Torella I; Franco E
    Ig Sanita Pubbl; 2009; 65(3):299-311. PubMed ID: 19629155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Q: Who should receive the shingles vaccine?
    Singh A; Englund K
    Cleve Clin J Med; 2009 Jan; 76(1):45-8. PubMed ID: 19122110
    [No Abstract]   [Full Text] [Related]  

  • 44. Live attenuated varicella vaccine.
    Arvin AM; Gershon AA
    Annu Rev Microbiol; 1996; 50():59-100. PubMed ID: 8905076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of vaccination on the epidemiology of varicella zoster virus.
    Edmunds WJ; Brisson M
    J Infect; 2002 May; 44(4):211-9. PubMed ID: 12099726
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Varicella-zoster vaccine for the prevention of herpes zoster.
    Kimberlin DW; Whitley RJ
    N Engl J Med; 2007 Mar; 356(13):1338-43. PubMed ID: 17392303
    [No Abstract]   [Full Text] [Related]  

  • 47. Live attenuated herpes zoster vaccine for HIV-infected adults.
    Shafran SD
    HIV Med; 2016 Apr; 17(4):305-10. PubMed ID: 26315285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008.
    Lu PJ; Euler GL; Harpaz R
    Am J Prev Med; 2011 Feb; 40(2):e1-6. PubMed ID: 21238856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In brief: Shingrix for immunocompromised adults.
    Med Lett Drugs Ther; 2021 Aug; 63(1631):129. PubMed ID: 34544099
    [No Abstract]   [Full Text] [Related]  

  • 50. Herpes zoster vaccine. Poorly effective in those who need it most.
    Prescrire Int; 2012 Dec; 21(133):291. PubMed ID: 23373094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Herpes zoster virus vaccine.
    Woolery WA
    Geriatrics; 2008 Oct; 63(10):6-9. PubMed ID: 18828650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Herpes zoster: diagnostic, therapeutic, and preventive approaches.
    Bader MS
    Postgrad Med; 2013 Sep; 125(5):78-91. PubMed ID: 24113666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Which patients should receive the herpes zoster vaccine?
    Short MD; Fergus C
    JAAPA; 2019 Sep; 32(9):18-20. PubMed ID: 31460969
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chickenpox vaccines: new drugs. A favourable risk-benefit balance in some situations.
    Prescrire Int; 2005 Jun; 14(77):85-91. PubMed ID: 15977369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Herpes zoster and postherpetic neuralgia - prevention by vaccination?].
    Wutzler P
    Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S90-4. PubMed ID: 19353479
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Reactivation of herpes zoster infection by varicella-zoster virus].
    Cvjetković D; Jovanović J; Hrnjaković-Cvjetković I; Brkić S; Bogdanović M
    Med Pregl; 1999; 52(3-5):125-8. PubMed ID: 10518396
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
    van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
    Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Herpes zoster and subunit vaccine].
    Imafuku S
    Uirusu; 2021; 71(1):45-54. PubMed ID: 35526994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.
    Tseng HF; Harpaz R; Luo Y; Hales CM; Sy LS; Tartof SY; Bialek S; Hechter RC; Jacobsen SJ
    J Infect Dis; 2016 Jun; 213(12):1872-5. PubMed ID: 26908728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.